NCT00267059View on ClinicalTrials.gov

Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)

PHASE2CompletedINTERVENTIONAL
Enrollment

45

Participants

Timeline

Start Date

December 31, 2005

Primary Completion Date

August 31, 2009

Study Completion Date

August 31, 2009

Conditions
Chronic Lymphocytic LeukemiaLeukemia
Interventions
DRUG

Lenalidomide

10 mg/day, orally once a day for 28 days

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Celgene Corporation
All Listed Sponsors
collaborator

Celgene Corporation

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER

NCT00267059 - Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL) | Biotech Hunter | Biotech Hunter